A Non-Interventional Retrospective Correlation Of Tumor Mutation Status To Clinical Benefit From The SU011248, A6181036 Treatment Protocol Titled: A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate [EXTENSION OF 700002518]
Latest Information Update: 03 Jul 2019
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Pfizer
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2013 New trial record